Blood Pressure Goal Missed By Two Thirds Of Patients - White Paper Addresses The Needs Of These “Challenging Patients”, Europe

Add comments

blood pressure control. The remaining two thirds are "challenging patients"
i.e. patients whose blood pressure physicians struggle to control. These are
Hypertension(1) by an international group of physicians calling for urgent
action. The group met to discuss the daily challenges European physicians
face
in the current critical situation of hypertension control. The outcome
is a consensus that continued failure to control hypertension inflicts an
unacceptable yet avoidable toll on patients, families and society.
anyone with blood pressure of 140/90 mmGeneric cipro pills no prescription Hg or greater". Whilst the current
perception is "close to goal is acceptable", the reality is that the majority
of challenging patients die prematurely or live with avoidable disability(2).
of Valencia, Spain; commented on the meeting and subsequent White Paper: "As
a group we concluded that any patient with blood pressure of 140/90 mmHg or
greater is at significant risk of cardiovascular disease progression, death
and or disability. As it is a challenge to get these patients to goal BP
these ‘challenging patients’ require persistent optimization of therapy until
estimated EUR192b annually(3). Control rates are significantly higher in
other developed countries(4). To address the current critical situation key
challenges were identified and effective solutions postulated, with a simple
aim: to treat all challenging patients effectively to goal BP, preventing
hypertension-driven cardiovascular disease.
inadequate primary prevention; (2) faulty awareness of risk; (3) lack of
simplicity
of treatment; (4) therapeutic inertia; (5) insufficient patient
empowerment; and (6) unsupportive healthcare systems.
clinicians can take six effective actions to (i) identify and (ii) reduce the
- Acknowledge their challenging patients & drive awareness of the dangers
- Encourage patients to take responsibility for their own cardiovascular
- Simplify treatment regimens by using the most effective and convenient
a randomised; double-blind multicentre study published in the latest issue of
Clinical Drug Investigation(5), which investigated simple, flexible treatment
regimens in a cohort of "challenging patients".
safety of an olmesartan/amlodipine single daily pill (SEVIKAR(R)) combination
therapy in patients with moderate to severe hypertension who had failed to
respond to treatment with 8 weeks of amlodipine. At randomization almost 75%
of these patients were in essence "challenging patients", i.e. unable to
achieve goal BP on amlodipine monotherapy.
BP reductions and rate of goal achievement than amlodipine 5 mg monotherapy
in as little as 8 weeks after treatment. Indeed more than 70% of challenging
patients on active combination therapy achieved their BP goal by week 24.
Results also demonstrated that appropriate uptitration of SEVIKAR(R) led to
further BP reductions and additional patients reaching BP goal, indicating
physician with flexibility to treat each individual patient’s needs.
situation that is close to clinical practice, highlighting the importance of
persistent optimization of therapy until target BP is achieved.
clinical studies demonstrating the ability of SEVIKAR(R) to successfully
treat patients with uncontrolled hypertension(6) (challenging patients) to
on researching and marketing innovative medications. The company was created
in 2005 through the merger of two traditional Japanese enterprises, Daiichi
and Sankyo. With net sales of more than 5.4 billion EUR in fiscal year 2007,
DAIICHI SANKYO is one of the world’s 20 leading pharmaceutical companies. The
company’s world headquarters is in Tokyo, and its European base is located in
Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been
one of the strongest Japanese pharmaceutical companies located in Europe
since it set up European production facilities and marketing offices in 1990.
diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to
develop medications that are "best" in their class or to create new classes
Buy generic ultram | generic clomid online buy | Buy viagra pills

January 23rd 2009 Uncategorized

Comments are closed.